{"id":"apg-157","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL4594459","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the production and function of granulocytes and macrophages, which are types of white blood cells that play a crucial role in the immune system. This can help to enhance the body's natural response to infection and inflammation.","oneSentence":"APG-157 is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:25.473Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT05312710","phase":"PHASE2","title":"Safety and Efficacy of APG-157 in Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aveta Biomics, Inc.","startDate":"2022-04-22","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx","enrollment":24},{"nctId":"NCT05865028","phase":"PHASE2","title":"A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia","status":"RECRUITING","sponsor":"Elizabeth J Franzmann","startDate":"2023-05-24","conditions":"Oropharyngeal Dysplasia, Oral Cavity Dysplasia, Oral Carcinoma in Situ","enrollment":32},{"nctId":"NCT06011109","phase":"PHASE1, PHASE2","title":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","status":"RECRUITING","sponsor":"Aveta Biomics, Inc.","startDate":"2023-12-13","conditions":"Glioma, Glioblastoma Multiforme","enrollment":30},{"nctId":"NCT05551013","phase":"","title":"Treatment of Recurrent GBM With APG-157 Via Expanded Access","status":"NO_LONGER_AVAILABLE","sponsor":"Aveta Biomics, Inc.","startDate":"","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"APG-157","genericName":"APG-157","companyName":"Aveta Biomics, Inc.","companyId":"aveta-biomics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APG-157 is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog. Used for Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}